Wegovy-Maker Novo Nordisk to Spend More Than $2 Billion Boosting Production in France
2023年11月24日 - 3:56AM
Dow Jones News
By Elena Vardon
Pharmaceutical giant Novo Nordisk said it will invest more than
16 billion Danish kroner ($2.34 billion) in its French production
site as it seeks to meet rising demand for its blockbuster obesity
and diabetes treatments.
The Danish company, which makes the Wegovy obesity drug and
diabetes drug Ozempic, said Thursday that the expansion of its
facility in Chartres, southwest of Paris, will more than double the
size of the site and is expected to create more than 500 new jobs.
Construction, which has already started and will employ up to 2,000
external workers, is set to complete between 2026 and 2028, it
said.
The site was set up in 1961 and currently employs around 1,600
people, Novo Nordisk said.
The group said earlier this month that it will invest more than
$6 billion to boost production capacity, most of which will be
dedicated to manufacturing active pharmaceutical ingredients used
to treat diabetes and obesity.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
November 23, 2023 13:41 ET (18:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novo Nordisk (NYSE:NVO)
過去 株価チャート
から 4 2024 まで 5 2024
Novo Nordisk (NYSE:NVO)
過去 株価チャート
から 5 2023 まで 5 2024
